Migrex 50 50 mg Tablet
PDF Leaflet Revision Date: 18 January 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Acute relief of migraine attacks.
Dosage (summary)
Initial dose 50 mg, may increase to 100 mg; max 300 mg in 24 hours.
Onset of Action / Duration
Onset: 30 mins, Duration: Not specified
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Safety in pregnancy not established; excreted in breast milk.
Key Drug Interactions
- Ergotamine
- MAOIs
- SSRIs
- SNRIs
Contraindications
- Hypersensitivity to sumatriptan
- Ischaemic heart disease
- Severe hypertension
- CVA or TIA history
- Severe hepatic impairment
Common side effects
- Dizziness
- Drowsiness
- Nausea
- Chest pain
- Flushing
Counselling Points
- Take at onset of migraine
- Do not exceed recommended dose
- Avoid in uncontrolled hypertension
- Monitor for allergic reactions
Serious warnings
- Risk of ischaemic heart disease
- Serotonin syndrome risk
- Caution in patients with cardiovascular risk factors
Important Disclaimer
The Migrex 50 50 mg Tablet professional information leaflet below is the property of Sandoz Sa 1 and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
